SMAD4 Antikörper (full length)

Produktnummer ABIN7879057

Der Maus Monoklonal anti-SMAD4 Antikörper (Klon SMAD4-2524) (ABIN7879057) detektiert spezifisch SMAD4 in ELISA. Dieser Antikörper reagiert spezifisch mit Proben aus Human.

Kurzübersicht für SMAD4 Antikörper (full length) (ABIN7879057)

Target: SMAD4 (SMAD Family Member 4 (SMAD4))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser SMAD4 Antikörper ist unkonjugiert

Applikation: ELISA

Güteklasse: Carrier-free

Klon: SMAD4-2524

Produktdetails anti-SMAD4 Antikörper

Bindungsspezifität: full length

Verwendungszweck: SMAD4 Antibody (azide and preservative free)

Aufreinigung: Protein G affinity chromatography

Immunogen: Recombinant full length human protein was used as the immunogen for this SMAD4 antibody.

Isotyp: IgG2a, kappa

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the SMAD4 antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Konservierungsmittel: Azide free

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store the SMAD4 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Details zu SMAD4

Target: SMAD4 (SMAD Family Member 4 (SMAD4))

Andere Bezeichnung: SMAD4

Hintergrund: Signaling from the ligand-activated membrane receptor serine/threonine kinases to nuclear targets is mediated by a set of evolutionarily conserved proteins known as DPC4. Upon ligand binding, the receptors of the TGF- family phosphorylate SMAD proteins (SMAD1 and SMAD2). These proteins then move into the nucleus, where they activate transcription. To carry out this function, the receptor activated SMAD1 and 2 require association with the product of deleted in pancreatic carcinoma, locus 4 (DPC4), also known as SMAD4. SMAD4/DPC4 is also implicated as a tumor suppressor, since it is inactivated in more than half of pancreatic carcinomas and to a lesser extent in a variety of other cancers. SMAD4 is absent in approximately 80 % of pancreatic adenocarcinoma, but rarely in endometrial, colorectal, ovarian, lung, breast adenocarcinomas, and malignant melanom. SMAD4 is an important marker for confirming a diagnosis of pancreatic adenocarcinoma. Patients with pancreatic adenocarcinomas with SMAD4 protein expression had significantly longer survival than SMAD4 negative patients.

UniProt: Q13485

Pathways: Zellzyklus, Chromatin Binding, Autophagie